These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26507307)

  • 41. Perioperative statin therapy.
    Chan WW; Wong GT; Irwin MG
    Expert Opin Pharmacother; 2013 May; 14(7):831-42. PubMed ID: 23521372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Performance of instrumental variable methods in cohort and nested case-control studies: a simulation study.
    Uddin MJ; Groenwold RH; de Boer A; Belitser SV; Roes KC; Hoes AW; Klungel OH
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):165-77. PubMed ID: 24306965
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices.
    Luijken K; Spekreijse JJ; van Smeden M; Gardarsdottir H; Groenwold RHH
    Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):960-974. PubMed ID: 33899305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Practice-based evidence research in rehabilitation: an alternative to randomized controlled trials and traditional observational studies.
    Horn SD; DeJong G; Deutscher D
    Arch Phys Med Rehabil; 2012 Aug; 93(8 Suppl):S127-37. PubMed ID: 22840879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estimating time-varying drug adherence using electronic records: extending the proportion of days covered (PDC) method.
    Bijlsma MJ; Janssen F; Hak E
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):325-32. PubMed ID: 26687394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.
    Berger ML; Dreyer N; Anderson F; Towse A; Sedrakyan A; Normand SL
    Value Health; 2012; 15(2):217-30. PubMed ID: 22433752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology.
    Cadarette SM; Maclure M; Delaney JAC; Whitaker HJ; Hayes KN; Wang SV; Tadrous M; Gagne JJ; Consiglio GP; Hallas J
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):671-684. PubMed ID: 33715267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are observational studies 'just as effective' as randomized clinical trials?
    Greene T
    Blood Purif; 2000; 18(4):317-22. PubMed ID: 10965074
    [No Abstract]   [Full Text] [Related]  

  • 49. Helping patients to reach decisions regarding their treatment: Do 'non-directive' approaches cause systematic bias?
    MacInnes JA; Salkovskis PM; Wroe A; Hope T
    Br J Health Psychol; 2015 Nov; 20(4):877-88. PubMed ID: 26286684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary non-adherence and the new-user design.
    Li X; Cole SR; Westreich D; Brookhart MA
    Pharmacoepidemiol Drug Saf; 2018 Apr; 27(4):361-364. PubMed ID: 29460385
    [No Abstract]   [Full Text] [Related]  

  • 51. Research on drug safety and effectiveness using pharmacoepidemiological databases.
    Andersen M
    J Intern Med; 2014 Jun; 275(6):548-50. PubMed ID: 24635741
    [No Abstract]   [Full Text] [Related]  

  • 52. Statin Adverse Events in Primary Prevention: Between Randomized Trials and Observational Studies.
    Mansi I
    Am J Med Sci; 2015 Oct; 350(4):330-7. PubMed ID: 26181083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Statin initiation and acute kidney injury following elective cardiovascular surgery: a population cohort study in Denmark†.
    Layton JB; Hansen MK; Jakobsen CJ; Kshirsagar AV; Andreasen JJ; Hjortdal VE; Rasmussen BS; Simpson RJ; Brookhart MA; Christiansen CF
    Eur J Cardiothorac Surg; 2016 Mar; 49(3):995-1000. PubMed ID: 26188012
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design issues for drug epidemiology.
    McMahon AD; MacDonald TM
    Br J Clin Pharmacol; 2000 Nov; 50(5):419-25. PubMed ID: 11069436
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Designing clinical trials for amblyopia.
    Holmes JM
    Vision Res; 2015 Sep; 114():41-7. PubMed ID: 25752747
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repeated interviews are much better for drug exposure assessment than a single baseline interview.
    Stricker BH
    Eur J Epidemiol; 2019 Nov; 34(11):993-995. PubMed ID: 31720949
    [No Abstract]   [Full Text] [Related]  

  • 57. When should case-only designs be used for safety monitoring of medical products?
    Maclure M; Fireman B; Nelson JC; Hua W; Shoaibi A; Paredes A; Madigan D
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():50-61. PubMed ID: 22262593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacoepidemiology: definition, methods and applications].
    Montastruc JL; Sommet A; Montastruc F; Moulis G; Bagheri H; Damase-michel C; Lapeyre-mestre M
    Bull Acad Natl Med; 2015; 199(2-3):263-73; discussion 273. PubMed ID: 27476308
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose-dependent effect of statins on the incidence of acute kidney injury after cardiac surgery.
    Mithani S; Kuskowski M; Slinin Y; Ishani A; McFalls E; Adabag S
    Ann Thorac Surg; 2011 Feb; 91(2):520-5. PubMed ID: 21256305
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.